SCHEMBL2193938

SCHEMBL2193938

CSCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
APC P25054 3/20 0.60
CCKBR P32239 8/20 0.56
CASP1 P29466 1/20 0.52
CASP3 P42574 1/20 0.52
CASP9 P55211 1/20 0.52
BACE1 P56817 1/20 0.52
OPRD1 P41143 5/20 0.50
OPRM1 P35372 4/20 0.50
OPRK1 P41145 1/20 0.50
FNTA P49354 1/20 0.49
FNTB P49356 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30568689 0.87 APC (0.57) APCCASP1CASP3CASP9
SCHEMBL2181857 0.85 CASP1 (0.62) APCCASP1CASP3CASP9
SCHEMBL2198063 0.85 APC (0.62) APCCASP1CASP3CASP9OPRD1
SCHEMBL16468879 0.83 CASP1 (0.58) APCCASP1CASP3CASP9
SCHEMBL30568698 0.83 CAPN1 (0.55) FNTAFNTB
SCHEMBL9596650 0.83 FNTA (0.58) CASP1CASP3CASP9FNTAFNTB
SCHEMBL11063969 0.83 OPRD1 (0.64) APCCCKBROPRD1OPRM1OPRK1
SCHEMBL2873941 0.82 MME (0.63) CASP1CASP3CASP9
SCHEMBL14778231 0.82 MME (0.63) CASP1CASP3CASP9
SCHEMBL11682400 0.82 REN (0.58) CCKBROPRD1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2019-03-07 US disclosed
US-9682153-B2 Polymer conjugates of therapeutic peptides NEKTAR THERAPEUTICS (US) 2017-06-20 US disclosed
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2016-01-28 US disclosed
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE NEKTAR THERAPEUTICS (US) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP APC 469/4885CCKBR 1004/4885CASP1 4042/4885
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP APC 469/4885CCKBR 1004/4885CASP1 4042/4885
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE DNPEP, VIP, PTMS APC 394/4885CCKBR 608/4885CASP1 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.